Research
Energy balance
Treatment with once-weekly injectable semaglutide resulted in a mean change in body weight of -13.7% compared to -3.2% with placebo (P<0.001).
Semaglutide may be an effective treatment for weight loss in obese individuals with knee osteoarthritis.
StrongSupportsmedium confidence
The mean change in body weight from baseline to week 68 was -13.7% with semaglutide and -3.2% with placebo (P<0.001).
Why this rating
Based on a large randomized controlled trial design.
Source
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Henning Bliddal et al. · New England Journal of Medicine · 2024
DOI 10.1056/nejmoa2403664
rct · n=407Cited 306×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide treatment led to a mean change in the WOMAC pain score of -41.7 points compared to -27.5 points with placebo (P<0.001).Strong
- Participants in the semaglutide group had a greater improvement in SF-36 physical-function score (mean change, 12.0 points) compared to the placebo group (mean change, 6.5 points; P<0.001).Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →